Press Release Jun 01 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
NATCO Pharma Limited has announced the launch of the first generic version of Nexavar (Sorafenib) Tablets in the U.S. market, as detailed in their press release. The product will be launched in collaboration with Viatris, a global pharmaceutical company. Sorafenib is used for treating various types of cancer, including Hepatocellular Carcinoma and Renal Cell Carcinoma.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from NATCO Pharma
- NATCO records INR 2043.8 Crore consolidated revenue and INR 170.0 Crore of profit, after tax, for the year ended March 31' 2022
- NATCO Announces Launch of the First Generic Version of Revlimid (Lenalidomide capsules), in the U.S. market
- Press Release Mar 07 2022
- NATCO announces License Agreement with the Medicines Patent Pool
- Press Release Jan 20 2022
Later from NATCO Pharma
- NATCO Announces Launch of First Generic Version of Nexavar (Sorafenib) Tablets in the U.S. Market
- Press Release Jul 25 2022
- NATCO records INR 918.9 Crore consolidated revenue and INR 320.4 Crore of profit, after tax, for the First Quarter, FY2022-23
- Press Release Aug 17 2022
- Press Release Sep 19 2022
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma